X VII
VÍSINDAR ÁÐSTEFNA
F YLGIRIT
HÍ
82
og gefur góð fyrirheit um að áfram megi halda smitsjúkdómum hérlendis í skefjum. Andstaða við bólusetningar og efasemdir um virkni
Hospital. A total of 500 women with a registered HTD during pregnancy (ICD-10, codes O10-16) were included as cases. Selected controls were
þeirra eru til staðar, þó ekki í miklu mæli.
1000 women without a HTD; matched on year of childbirth (1:2). BMI was based on measures before 15 weeks of pregnancy. We used logistic regression models to calculate odds ratios (OR), and corresponding
V 60 Patient adherence to TNFα inhibitors in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA)
95% confidence intervals (CI), as measures of association, adjusting for potential confounders. Analyses were conducted stratified by smoking status.
Þórunn Óskarsdóttir1, Anna Ingibjörg Gunnarsdóttir1,2, Pétur Sigurður Gunnarsson1,2, Þorvarður J. Löve1,3, Björn Guðbjörnsson1,3 Landspítali University Hospital, 2Faculty of Pharmacology, University of Iceland, 3Faculty of Medicine, University of Iceland
1
[email protected]
Results: Women’s BMI was associated with all types of HTD during pregnancy. Compared with normal weight women, the multivariable adjusted OR for any HTD was 1.8 (95% CI 1.3-2.3) for overweight
Introduction: Patient adherence to treatment plays a fundamental role in clinical outcome. The objective of this study was to calculate patient
women and 3.1 (95% CI 2.2-4.3) for obese women. The OR for any HTD with obesity was higher among smokers (OR=3.9, 95% Cl 1.8-8.6) than non-smokers (OR=3.0, 95% CI 2.1-4.3).
adherence to treatment with TNFα inhibitors (adalimumab, etanercept and infliximab) in RA and PsA. Methods and data: Observational cohort study based on two registries:
Conclusions: Overweight and obese women are at considerable risk for all types of hypertensive disorders during pregnancy as compared with normal weight women. This risk is enhanced even further with
ICEBIO and the prescription registry systems at Landspitali. The present study included 499 patients registered in ICEBIO (321=RA; 178=PsA). All patients were receiving their first biologic treatment during the study period (2009–2013). Medication adherence was calculated using medication possession ratio (MPR) and proportion of days covered (PDC) to create an adherence score, which was used to classify patients as adherent (≥80% for either score) or non-adherent. Results: Of the 499 patients 53% received infliximab, 34% etanercept, and 13% adalimumab. Patients treated with infliximab were more likely to adhere to treatment than those treated with etanercept or adalimumab (p
